Studies have demonstrated that ZYIL1 can selectively supress inflammation caused by the NLRP3 inflammasome
Ahmedabad-based Zydus has received permission to initiate the Phase 1 clinical trial of ZYIL1, a novel oral small molecule NLRP3 inhibitor candidate.
NLRP3 inflammasomes are involved in the inflammation process by production and release of pro-inflammatory cytokines IL-1β and IL-18. This harmful inflammation within the body leads to the onset and development of various kinds of diseases, including Acute Respiratory Distress Syndrome (ARDS), auto-immune diseases, inflammatory diseases, cardiovascular diseases, metabolic disorders, gastro-intestinal diseases (inflammatory bowel disease, IBD), renal diseases and CNS diseases.
Speaking on the development, Pankaj Patel, Chairman, Cadila Healthcare, said, “We will study the safety, tolerability, pharmacokinetics and pharmacodynamics of ZYIL1 in this Phase I clinical trial in healthy human volunteers. We are committed to developing these pioneering novel treatments to the clinic for the patients in need.”
ZYIL1 has reportedly demonstrated promising efficacy in a number of validated pre-clinical models of IBD, Multiple Sclerosis (MS), sepsis and acute lung injury models of ARDS. The studies have demonstrated that ZYIL1 can selectively supress inflammation caused by the NLRP3 inflammasome. The candidate reportedly has an acceptable ADME profile, with high safety margin.
- Advertisement -